Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial

(2015) Sirwan M. Hadad et al.   BREAST CANCER RESEARCH AND TREATMENT

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2015) Sil Kordes et al.   LANCET ONCOLOGY

Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3)

(2015) Xiaomin Liang et al.   MOLECULAR PHARMACEUTICS

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)

(2015) M Joerger et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?

(2015) Diana Hatoum et al.   Biomed Research International

Second-generation PLINK: rising to the challenge of larger and richer datasets

(2015) Christopher C Chang et al.   GigaScience

Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo

(2015) Xianbin Cai et al.   PLoS One

Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin

(2014) S Goswami et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metformin Pharmacogenomics: Biomarkers to Mechanisms

(2014) L. Wang et al.   DIABETES

A Divergent Role of the SIRT1-TopBP1 Axis in Regulating Metabolic Checkpoint and DNA Damage Checkpoint

(2014) Tongzheng Liu et al.   MOLECULAR CELL

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

(2014) Kıvanç Birsoy et al.   NATURE

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment

(2014) Michael Pollak   NATURE MEDICINE

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery

(2014) Mihaela Aldea et al.   TUMOR BIOLOGY

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

(2014) Kaixin Zhou et al.   Lancet Diabetes & Endocrinology

Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney

(2013) Hideyuki Motohashi et al.   AAPS Journal

A Proposal Regarding Reporting of In Vitro Testing Results

(2013) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray

(2013) Yi-an Chen et al.   Epigenetics

DNA methylation contributes to natural human variation

(2013) H. Heyn et al.   GENOME RESEARCH

Potential applications for biguanides in oncology

(2013) Michael Pollak   JOURNAL OF CLINICAL INVESTIGATION

CHIP protects against cardiac pressure overload through regulation of AMPK

(2013) Jonathan C. Schisler et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacogenetics of Oral Antidiabetic Drugs

(2013) Matthijs L. Becker et al.   International Journal of Endocrinology

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system

(2013) Jing Jiang et al.   Frontiers in Genetics

Metformin is synthetically lethal with glucose withdrawal in cancer cells

(2012) Javier A. Menendez et al.   CELL CYCLE

Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers

(2012) Xin-Sheng Deng et al.   CELL CYCLE

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

(2012) N. van Leeuwen et al.   DIABETOLOGIA

Sumoylation of MDC1 is important for proper DNA damage response

(2012) Kuntian Luo et al.   EMBO JOURNAL

Diabetes, Metformin, and Breast Cancer in Postmenopausal Women

(2012) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin pathways

(2012) Li Gong et al.   Pharmacogenetics and Genomics

Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

(2012) Michael N. Pollak   Cancer Discovery

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

(2011) Bolin Liu et al.   CELL CYCLE

Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1

(2011) H Gaude et al.   ONCOGENE

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

(2011) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates

(2010) Randy Suryadinata et al.   BIOSCIENCE REPORTS

Diabetes and Cancer: A Consensus Report

(2010) E. Giovannucci et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

(2010) K. A. Jablonski et al.   DIABETES

Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines

(2010) N. Niu et al.   GENOME RESEARCH

Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors

(2010) James N. Ingle et al.   JOURNAL OF CLINICAL ONCOLOGY

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

(2010) Kaixin Zhou et al.   NATURE GENETICS

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

(2010) Ligong Chen et al.   Pharmacogenetics and Genomics

Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions

(2010) G Ahlin et al.   PHARMACOGENOMICS JOURNAL

DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells

(2009) Simone Bork et al.   AGING CELL

Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

(2009) M. L. Becker et al.   DIABETES

Stress-dependent Daxx-CHIP Interaction Suppresses the p53 Apoptotic Program

(2009) Holly McDonough et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function

(2009) Ying Chen et al.   PHARMACOGENOMICS JOURNAL

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

(2009) M L Becker et al.   PHARMACOGENOMICS JOURNAL

Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression

(2008) L. Li et al.   CANCER RESEARCH

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes

(2008) I. S. Song et al.   XENOBIOTICA